Table 2.
Key Characteristics of Eligible Studies
| Study, Phase, First Author (Year) | Treatment | Primary Site | Lung NET (n)/Patients Enrolled | Lung NET Treated with Eve (n) | Line of Therapy | Association with SSA |
|---|---|---|---|---|---|---|
| RADIANT-2, Phase III Pavel ME (2011)59 |
EVE 10 mg + OCT LAR 30 mg or placebo + OCT LAR 30 mg | Mixed NET | 44/429 | 33 | ANY | YES (100%) (OCT LAR 30mg q28) |
| Lung subgroup analysis RADIANT-2, phase III Fazio N (2013)60 |
EVE 10 mg + OCT LAR 30 mg or placebo + OCT LAR 30 mg | Lung NET | 44/429 | 33 | ANY | YES (100%) (OCT LAR 30mg q28) |
| RADIANT-4, phase III Yao JC (2015)61 |
EVE 10 mg or placebo | Mixed NET | 90/302 | 63 | ANY (1L 39%) |
0% |
| Lung subgroup analysis RADIANT-4, phase III Fazio N (2017)62 |
EVE 10 mg or placebo | Lung NET | 90/302 | 63 | ANY (1L 14 vs 11) |
0% |
| ITMO, Phase II Bajetta E (2014)63 |
EVE 10 mg + OCT LAR 30 mg | Mixed NET | 11/50 | 11 | FIRST | YES (100%) (OCT LAR 30mg q28) |
| LUNA, Phase II Ferolla (2017)65 |
PAS or EVE 10 mg or combination | Lung and thymus NET | 116/124 | 78 | 1L (%): 29 vs 36 vs 32 | Only the combination arm (EVE+PAS) |
Abbreviations: EVE, everolimus; OCT, Octreotide; NET, neuroendocrine tumor; SSA, somatostatin analogue; PAS, pasireotide.